Mersana Therapeutics

Search
  • About
    • Mission & Vision
    • Executive Team
    • Board of Directors
    • Scientific Advisory Board
    • ESG
    • Collaborations
  • Platforms
    • About ADCs
    • Dolasynthen
    • Immunosynthen
  • Pipeline
    • Overview
    • XMT-1660
    • XMT-2056
  • Publications
  • Investors & Media
    • Overview
    • Stock
    • Analysts
    • SEC Filings
    • News
    • Events
    • Annual Meeting
    • Governance
    • Quarterly Results
    • Contact Us
  • People
    • Culture
    • Benefits
    • Careers
  • Contact
Dolasynthen, Other, Publications

Site-Specific Dolasynthen Antibody-Drug Conjugates Exhibit Consistent Pharmacokinetic Profiles Across a Wide Range of Drug to Antibody Ratios

Immunosynthen, Other, Publications

Discovery and Optimization of a STING Agonist Platform for Application in Antibody Drug Conjugates

Dolasynthen, Publications, XMT-1660

Discovery and Preclinical Characterization of XMT-1660, an Optimized B7-H4-Targeted Antibody-Drug Conjugate for the Treatment of Cancer

Other, Other, Publications

UPGRADE-A: Phase 1 Expansion Trial of the NaPi2b-Directed Antibody Drug Conjugate Upifitamab Rilsodotin in Combination With Carboplatin in Patients With High-Grade Serous Ovarian Cancer

Other, Other, Publications

Correlating Expression of NaPi2b and Folate Receptor Alpha (FRα) in High‑Grade Serous Ovarian Cancer (HGSOC)

Other, Other, Publications

UP‑NEXT (GOG‑3049/ENGOT‑ov71‑NSGO‑CTU): A Study of Upifitamab Rilsodotin (UpRi), a NaPi2b‑directed Antibody‑Drug Conjugate in Platinum‑Sensitive Recurrent Ovarian Cancer

Dolasynthen, Publications, XMT-1660

XMT‑1660: A Phase 1b Trial of a B7‑H4–Targeting Antibody‑Drug Conjugate (ADC) in Breast, Endometrial, and Ovarian Cancers

Other, Other, Publications

Advances in Ovarian Cancer Care and Unmet Treatment Needs for Patients with Platinum Resistance

Immunosynthen, Publications, XMT-2056

XMT-2056, a HER2-Directed STING Agonist Antibody-Drug Conjugate, Exhibits ADCC Function that Synergizes with STING Pathway Activation and Contributes to Anti-tumor Responses

Other, Other, Publications

The Evolving Landscape of Antibody-Drug Conjugates in Gynecologic Cancers

© 2023 Mersana Therapeutics, All Rights Reserved. Privacy Policy | Terms of Use
linkedin icon twitter icon
logo
  • About
    • Mission & Vision
    • Executive Team
    • Board of Directors
    • Scientific Advisory Board
    • ESG
    • Collaborations
  • Platforms
    • About ADCs
    • Dolasynthen
    • Immunosynthen
  • Pipeline
    • Overview
    • XMT-1660
    • XMT-2056
  • Publications
  • Investors & Media
    • Overview
    • Stock
    • Analysts
    • SEC Filings
    • News
    • Events
    • Annual Meeting
    • Governance
    • Quarterly Results
    • Contact Us
  • People
    • Culture
    • Benefits
    • Careers
  • Contact